Wedbush Securities’s Anixa Biosciences ANIX Stock Holding History

Wedbush Securities’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,000	Closed	-$34K	–	857
2017 Q3	$34K	Buy	+13,000	New	+$14.3K	﹤0.01%	815

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIA

Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CAM

Concorde Asset Management Ann Arbor, Michigan $204M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wedbush Securities's ANIX Position: Q4 2017 in Review

Wedbush Securities sold out of Anixa Biosciences (ANIX) in Q4 2017, closing a stake of 13,000 shares — an estimated $34K sold.

Wedbush Securities first reported a position in ANIX in Q3 2017 and held it in 1 quarter. The position peaked at $34K in Q3 2017. 18 funds tracked by Wall St. Rank hold ANIX as of Q4 2017.

Wedbush Securities reported no remaining Anixa Biosciences position as of Q4 2017 after selling out during the quarter.
Wedbush Securities sold 13,000 Anixa Biosciences shares in Q4 2017, an estimated $34K.
Wedbush Securities first reported a position in Anixa Biosciences in Q3 2017 and held it in 1 quarter.
Wedbush Securities's Anixa Biosciences position peaked at $34K in Q3 2017.
18 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2017.

Based on Wedbush Securities's 13F filing for Q4 2017, filed 9 Feb 2018.